The state’s ambitious payment overhaul has begun to demonstrate savings and a change in culture, say new reports.
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.
Months of reporting and rich hospital data portray life in the worst asthma hot spot in one of the worst asthma cities: Baltimore. The medical system knows how to help. But there’s no money in it.
Es esencial que conozca sus opciones en base a los ingresos y al tamaño de su familia. Aquí, algunas respuestas clave para entender el mercado de seguros.
This year, more than ever, it is important to know your options.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The Senate draft bill released Thursday to replace the Affordable Care Act risks creating a high-cost ghetto for those with preexisting conditions or long-term sickness, experts say.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Los peores enemigos de la Ley de Cuidado de Salud Asequible ahora están a cargo. Y están discutiendo cambios que podrían afectar a una más amplia red de planes de empleadores y a la cobertura del Medicare para los adultos mayores.
There are many ways beyond legislative repeal for the Trump administration and congressional Republicans to unravel the Affordable Care Act.